PhRMA elects new board members, adds member company
WASHINGTON — The Pharmaceutical Research and Manufacturers of America on Tuesday officially elected new board members and welcomed its latest member company, UBC.
Johnson & Johnson worldwide chairman, pharmaceuticals Joaquin Duato was elected chairman of the board, a position he assumed in early January following the departure of Biogen’s George Scangos. Novartis CEO Joseph Jimenez was elected chairman-elect and Amgen chairman and CEO Robert Bradway was named board treasurer.
“I am pleased to welcome Joaquin Duato, Joseph Jimenez and Robert Bradway to their new leadership roles at PhRMA and UCB as a new member,” PhRMA president and CEO Stephen Ubl said. “I, and our entire team, look forward to working with them to convene stakeholders across the health care system to discuss new innovative ways to pay for medicines and advance patient-focused solutions. Biopharmaceutical science is advancing faster than ever before, and we need to make sure we have a payment and reimbursement system that is as innovative as the medicines produced by our companies.”
Jimenez has been CEO at Novartis since 2010 after joining the company in 2007 as division head of its consumer health segment, becoming division head of Novartis Pharmaceuticals before rising to the CEO position.
“For patients to truly benefit from the new era of medicine, there is a critical need for greater collaboration in the health care ecosystem,” Jimenez said. “PhRMA is making important strides in this effort, and I look forward to more widely representing the industry in the move toward a value-driven health care system.”
Bradway has been chairman at Amgen since 2013 and CEO since 2012. He joined the company in 2006, serving as president and COO before becoming CEO. He was previously a managing director at Morgan Stanley in London and is a member of the boards of Norfolk Southern and Boeing. He is a member of the board of trustees of the University of Southern California and the advisory board of the Leonard D. Schaeffer Center for Health Policy and Economics at USC. He is the chairman of the CEO Roundtable on Cancer.
“Helping patients and addressing the burden of disease is what drives the men and women of this industry every single day,” Bradway said. “We are seeing the power of innovation in every aspect of today’s approaches to medical discovery and are eager to demonstrate how bold advancements in innovation can address the costs of disease.”
PhRMA’s newest member company, UBC, is based in Brussels, Belgium and is a biopharmaceutical company with a focus on developing treatments for patients with severe diseases in immunology and neurology. It generated revenue of more than $4 billion in 2015.